» Articles » PMID: 37511515

The Molecular Mechanisms of Neuroinflammation in Alzheimer's Disease, the Consequence of Neural Cell Death

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jul 29
PMID 37511515
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is accompanied by neural cell loss and memory deficit. Neural cell death, occurring via apoptosis and autophagy, is widely observed in the AD brain in addition to neuroinflammation mediated by necroptosis and the NLRP3 inflammasome. Neurotoxicity induced by amyloid-beta (Aβ) and tau aggregates leads to excessive neural cell death and neuroinflammation in the AD brain. During AD progression, uncontrolled neural cell death results in the dysregulation of cellular activity and synaptic function. Apoptosis mediated by pro-apoptotic caspases, autophagy regulated by autophagy-related proteins, and necroptosis controlled by the RIPK/MLKL axis are representative of neural cell death occurred during AD. Necroptosis causes the release of cellular components, contributing to the pro-inflammatory environment in the AD brain. Inordinately high levels of neural cell death and pro-inflammatory events lead to the production of pro-inflammatory cytokines and feed-forward hyper neuroinflammation. Thus, neural cell death and neuroinflammation cause synaptic dysfunction and memory deficits in the AD brain. In this review, we briefly introduce the mechanisms of neural cell death and neuroinflammation observed in the AD brain. Combined with a typical strategy for targeting Aβ and tau, regulation of neural cell death and neuroinflammation may be effective for the amelioration of AD pathologies.

Citing Articles

Behavioral and histological study on the neuroprotective effect of thymoquinone on the cerebellum in AlCl3-induced neurotoxicity in rats through modulation of oxidative stress, apoptosis, and autophagy.

Shrief A, Elshenawy D, Elsukary A, Elekhtiar S, Yahia O J Mol Histol. 2025; 56(2):81.

PMID: 39912993 DOI: 10.1007/s10735-025-10361-2.


The Interplay Between Accumulation of Amyloid-Beta and Tau Proteins, PANoptosis, and Inflammation in Alzheimer's Disease.

Zhuang X, Lin J, Song Y, Ban R, Zhao X, Xia Z Neuromolecular Med. 2025; 27(1):2.

PMID: 39751702 DOI: 10.1007/s12017-024-08815-z.


Bioactivated Glucoraphanin Improves Cell Survival, Upregulating Phospho-AKT, and Modulates Genes Involved in DNA Repair in an In Vitro Alzheimer's Disease Model: A Network-Transcriptomic Analysis.

Minuti A, Mazzon E, Iori R, Chiricosta L, Artimagnella O Nutrients. 2024; 16(23).

PMID: 39683594 PMC: 11644231. DOI: 10.3390/nu16234202.


Navigating the Alzheimer's Biomarker Landscape: A Comprehensive Analysis of Fluid-Based Diagnostics.

El Abiad E, Al-Kuwari A, Al-Aani U, Al Jaidah Y, Chaari A Cells. 2024; 13(22).

PMID: 39594648 PMC: 11593284. DOI: 10.3390/cells13221901.


Different amyloid β42 preparations induce different cell death pathways in the model of SH-SY5Y neuroblastoma cells.

Ozdemir A, Hofbauerova K, Kopecky Jr V, Novotny J, Rudajev V Cell Mol Biol Lett. 2024; 29(1):143.

PMID: 39551742 PMC: 11572474. DOI: 10.1186/s11658-024-00657-8.


References
1.
Cao Z, Xiong J, Takeuchi M, Kurama T, Goeddel D . TRAF6 is a signal transducer for interleukin-1. Nature. 1996; 383(6599):443-6. DOI: 10.1038/383443a0. View

2.
Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

3.
Stoppelkamp S, Bell H, Palacios-Filardo J, Shewan D, Riedel G, Platt B . In vitro modelling of Alzheimer's disease: degeneration and cell death induced by viral delivery of amyloid and tau. Exp Neurol. 2011; 229(2):226-37. DOI: 10.1016/j.expneurol.2011.01.018. View

4.
Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E . Autophagic programmed cell death by selective catalase degradation. Proc Natl Acad Sci U S A. 2006; 103(13):4952-7. PMC: 1458776. DOI: 10.1073/pnas.0511288103. View

5.
Li S, Qu L, Wang X, Kong L . Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment. Pharmacol Ther. 2021; 231:107979. DOI: 10.1016/j.pharmthera.2021.107979. View